All In Biotech

NDA 021735 · Fougera

Terconazole

Terconazole · Vaginal · Azole Antifungal

Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Oct 1, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

5 Phase 3, 0 recruiting

FAERS reports

831

456 serious, 23 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 28, 2026.

Terconazole Vaginal Cream, is indicated for the treatment of vulvovaginal candidiasis in adult females. Terconazole Vaginal Cream is an azole antifungal indicated for the treatment of vulvovaginal candidiasis in adult females. ( 1 )

Mechanism: Terconazole is an antifungal agent [see Microbiology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 1, 2004 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • TERCONAZOLE · TERCONAZOLE 0.8% · CREAM, VAGINAL · Prescription · TE BX

Clinical trials

Interventional ClinicalTrials.gov studies with "Terconazole" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain96
  • chronic kidney disease68
  • drug ineffective57
  • nausea50
  • anxiety49
  • headache46
  • urinary tract infection43
  • fatigue40
  • product quality issue40
  • acute kidney injury37
  • emotional distress36
  • pain in extremity33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20063
20074
20088
200913
201014
201130
201223
201340
201431
201541
201655
201740
201888
201999
202086
202162
202248
202340
202427
202537
202641

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Terconazole (Terconazole)

2024 spending

$3.7M

Beneficiaries

87,657

128,154 claims

Per beneficiary

$42

$1.72 per unit

View as table
YearSpending
2020$4,426,074
2021$4,182,669
2022$4,192,495
2023$4,059,954
2024$3,704,524

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 22 on PubMed

Sponsor: Fougera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.